Document Detail


Prognostic significance of imaging contrast enhancement for WHO grade II gliomas.
MedLine Citation:
PMID:  18697954     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In this study, we investigated the prognostic value of MRI contrast enhancement (CE) at the time of histological diagnosis specifically in a selected population of WHO grade II gliomas. We reviewed 927 histologically proven WHO grade II gliomas for which contrast-enhanced MR images were available at the time of histological diagnosis. CE patterns were classified into three categories: "patchy and faint," "nodular-like," and "ring-like." CE progression over time was recorded before oncological treatment on successive MR images, when available. CE was present in 143 cases (15.9%), with 93 patchy and faint, 50 nodular-like, and no ring-like patterns. CE areas were time progressive before oncological treatment in 35 of the 56 available cases (62.5%). Regardless of its pattern, the presence of CE was not significantly associated with a worsened prognosis (p = 0.415) by univariate analysis. Only the nodular-like pattern of CE (p < 0.01) and the time-progressive CE (p < 0.001) in the available subgroup proved to be statistically associated with survival since first oncological treatment. The present results show the necessity, in cases of WHO grade II gliomas, to study CE at the time of histological diagnosis and, whenever possible, to follow its progression over time before oncological treatment. Nodular-like CE and time-progressive CE are associated with a worsened prognosis, both suggesting malignant transformation, even though histopathological examination cannot initially disclose signs of malignancy in those areas.
Authors:
Johan Pallud; Laurent Capelle; Luc Taillandier; Denys Fontaine; Emmanuel Mandonnet; Rémy Guillevin; Luc Bauchet; Philippe Peruzzi; Florence Laigle-Donadey; Michèle Kujas; Jacques Guyotat; Marie-Hélène Baron; Karima Mokhtari; Hugues Duffau
Related Documents :
17218134 - Spectral editing in solid-state mas nmr of quadrupolar nuclei using selective satellite...
1987204 - "dural tail sign": a specific mr sign for meningioma?
16374284 - Real-time, contrast-enhanced sonography: a new tool for detecting active bleeding.
18632394 - Improving iris recognition performance using segmentation, quality enhancement, match s...
6874944 - Intraoperative bone imaging in the treatment of osteoid osteoma of the femoral neck.
6836134 - Ultrasonography in testicular torsion.
Publication Detail:
Type:  Journal Article     Date:  2008-08-12
Journal Detail:
Title:  Neuro-oncology     Volume:  11     ISSN:  1522-8517     ISO Abbreviation:  Neuro-oncology     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-01     Completed Date:  2009-05-06     Revised Date:  2010-09-21    
Medline Journal Info:
Nlm Unique ID:  100887420     Medline TA:  Neuro Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  176-82     Citation Subset:  IM    
Affiliation:
Department of Neurosurgery, Hôpital de la Pitié-Salpêtrière, Paris, INSERM U678, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Brain Neoplasms / diagnosis*
Contrast Media / diagnostic use*
Female
Gadolinium DTPA / diagnostic use*
Glioma / diagnosis*
Headache Disorders / diagnosis
Humans
Image Enhancement
Magnetic Resonance Imaging*
Male
Middle Aged
Nervous System Diseases / diagnosis
Prognosis
Seizures / diagnosis
Survival Rate
Young Adult
Chemical
Reg. No./Substance:
0/Contrast Media; 80529-93-7/Gadolinium DTPA
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-micr...
Next Document:  High-grade glioma before and after treatment with radiation and Avastin: initial observations.